secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001104659-24-124597
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode raises ~$8M in private placement; expects to regain Nasdaq compliance
-------------------------------------------------------------------------------

- Issued 21.2M shares/pre-funded warrants, 21.2M Series C and 21.2M Series D warrants at $0.377/unit.
- Warrants exercisable at $0.475; Series C 5-year term, Series D 2.5-year term after stockholder approval.
- Gross proceeds ~$8M; proceeds for working capital and general corporate purposes.
- Regained compliance with Nasdaq $2.5M minimum equity requirement after private placement; awaiting final determination.
- Benchmark Company acted as exclusive placement agent; cash fee $50,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924124597/0001104659-24-124597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924124597/tm2429720d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-124597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer